Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Telix Pharmaceuticals Ltd.

http://www.telixpharma.com

Latest From Telix Pharmaceuticals Ltd.

The IPO Queue Fills Up, But A Recovery Is A Way Off

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Financing Commercial

IPOs Collapse In The Second Quarter

Biotechs have had a difficult time raising cash through flotations over the past quarter, with one stepping away altogether.

Financing Business Strategies

Finance Watch: Alumis Launches IPO In Market Less Receptive Than Expected

Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.

Financing Business Strategies

Telix Scuttles Its US Listing

The radiopharmaceutical developer abandoned its NASDAQ IPO at the eleventh hour. What now?

Commercial Companies
See All

Company Information

UsernamePublicRestriction

Register